European Union
International Standa...
NGOs
United Nations
Aland Islands
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia & Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Faroe Islands
Finland
France
Georgia
Germany
Gibraltar
Greece
Guernsey
Hungary
Iceland
Ireland
Isle of Man
Italy
Jersey
Kazakhstan
Latvia
Liechtenstein
Lithuania
Luxembourg
Macedonia
Malta
Moldova
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Romania
Russia
San Marino
Serbia
Slovakia
Slovenia
Spain
Svalbard & Jan Mayen...
Sweden
Switzerland
Turkey
Ukraine
United Kingdom
Vatican City State (...
|
GeorgiaEuropean Commission Medical Devices Expert Group
| Report Title: |
Report on Nanotechnology to the Medical Devices Expert Group: Findings and Recommendations |
| Report ID: |
480 |
| Date: |
7/27/2007 |
| Author: |
Working Group on New and Emerging Technologies in Medical Devices (N&ET Working Group) |
| Report Type: |
Committee Report |
| URL: |
[document.cfm] |
| Country: |
European Union |
| Organization: |
European Commission Medical Devices Expert Group |
| Summary: |
The New and Emerging Technology Working Group, a sub-group of the Medical Devices Expert Group which advises the European Commission on medical devices, aimed in this report to consider the adequacy of the existing regulations in managing the use of nanotechnology in medical devices. Generally, the Working Group considers existing legislation suitable for dealing with medical devices using nanotechnology. The existing risk management approach of the regulations appropriately covers new risks such as nanotechnology. Nanotechnology concerns are concentrated on the potential for free nanoparticles. However, there possibly could be a specific classification rule moving nanomaterial products into Class III, which is a device class requiring case-by-case risk assessment. Although products coated in nanoparticles pose a risk of releasing free nanoparticles during use, this risk is very similar to that of traditional implants (e.g. hip replacements) which also can create particles through wear. There needs to be a post-market surveillance system to ensure that nanomaterial-containing devices are as safe as expected, and the methods by which risks will be examined under the present legislation must be developed further. |
| Archived Copy: |
medicaldevices_480_7157.pdf |
 |
|
|